Related Experiment Videos
Antithrombotic therapy in the coronary vein graft patient
D H Israel1, P C Adams, B Stein
1Division of Cardiology, Mount Sinai School of Medicine, New York, NY 10029.
Insights
Platelet inhibitors and anticoagulants help prevent saphenous vein graft occlusion after coronary artery bypass grafting. These medications address thrombosis and intimal hyperplasia, improving long-term graft patency.
Area of Science:
- Cardiovascular Surgery
- Vascular Biology
- Pharmacology
Background:
- Coronary artery bypass grafting (CABG) is a key treatment for coronary artery disease.
- Saphenous vein graft disease limits long-term CABG success.
- Graft occlusion involves thrombosis, intimal hyperplasia, and atherosclerosis.
Purpose of the Study:
- To review the role of antiplatelet and anticoagulant therapies.
- To explore prevention strategies for saphenous vein graft occlusion.
- To understand the mechanisms of early and late graft failure.
Main Methods:
- Literature review of platelet inhibitors and anticoagulants.
- Analysis of pathogenetic mechanisms of vein graft disease.
- Synthesis of evidence on therapeutic interventions.
Main Results:
- Early graft occlusion is mainly thrombotic.
- Late occlusion involves thrombosis on intimal hyperplasia or atherosclerosis.
- Pharmacological agents target these specific mechanisms.
Conclusions:
- Platelet inhibitors and anticoagulants are crucial for preventing vein graft occlusion.
- Targeting thrombotic and hyperplastic processes improves graft survival.
- Pharmacotherapy enhances long-term outcomes following CABG.
Abstract:
Coronary artery bypass grafting is an important therapeutic modality in the treatment of the patient with coronary artery disease; however, long-term results are limited by the development of saphenous vein graft disease early and late after operation. The pathogenesis of early vein graft occlusion is primarily thrombotic, while that occurring later frequently involves thrombosis superimposed on intimal hyperplasia or vein graft atherosclerosis. We describe the role of various platelet inhibitors and anticoagulants in the prevention of saphenous vein graft occlusion following coronary artery bypass grafting.